Skip to main content

Table 1 Patients’ demographic and baseline fertility characteristics overall and by treatment group (primary efficacy analysis population)

From: Phase IV, open-label, randomized study of low-dose recombinant human follicle-stimulating hormone protocols for ovulation induction

Variable

CLD group

LD group

Total

(n = 122)

(n = 125)

(N = 247)

Age, years a

n

122

124

246

 

Mean (SD)

27.5 (4.42)

27.9 (4.33)

27.7 (4.37)

BMI, kg/m 2 a

n

119

124

243

Mean (SD)

26.4 (2.95)

26.0 (3.14)

26.2 (3.05)

Race b

n

122

124

246

Arab

n (%)

68 (55.7)

69 (55.6)

137 (55.7)

Asian

n (%)

19 (15.6)

16 (12.9)

35 (14.2)

Black

n (%)

1 (0.8)

4 (3.2)

5 (2.0)

Caucasian

n (%)

33 (27.1)

34 (27.4)

67 (27.2)

Other

n (%)

1 (0.8)

1 (0.8)

2 (0.8)

Infertility type b

n

122

125

247

Primary

n (%)

92 (75.4)

96 (76.8)

188 (76.1)

Secondary

n (%)

30 (24.6)

29 (23.2)

59 (23.9)

Duration of infertility, years a

n

122

125

247

 

Mean (SD)

3.8 (2.57)

4.2 (2.48)

4.0 (2.53)

Cause of infertility b

n

123c

127c

250c

Ovulatory dysfunction

n (%)

120 (97.6)

121 (95.3)

241 (96.4)

Tubal factor

n (%)

0 (0.0)

1 (0.8)

1 (0.4)

Other

n (%)

3 (2.4)

5 (3.9)

8 (3.2)

Previous infertility treatment b

n

122

125

247

Yes

n (%)

90 (73.8)

103 (82.4)

193 (78.1)

No

n (%)

32 (26.2)

22 (17.6)

54 (21.9)

Previous pregnancies b

n

122

125

247

None

n (%)

92 (75.4)

94 (75.2)

186 (75.3)

At least one

n (%)

30 (24.6)

31 (24.8)

61 (24.7)

  1. aNot significant; t-test.
  2. bNot significant; Chi-square test.
  3. cMultiple causes of infertility in three patients (CLD group, n = 1; LD group, n = 2).
  4. BMI = body mass index; CLD = chronic low-dose; LD = low-dose; SD = standard deviation.